/HCAT
HCAT Stock - Health Catalyst, Inc.
Healthcare|Medical - Healthcare Information ServicesNASDAQ
$2.40-2.44%
$0.06 (-2.44%) • Jan 13
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.8
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.52
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+102.5%upside
Target: $4.86
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HCAT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.38 – $2.42
TARGET (TP)$4.86
STOP LOSS$2.21
RISK/REWARD1:12.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.70
52W High$6.60
52W Low$2.02
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $306.58M | $295.94M | $276.24M | $241.93M | $188.84M |
| Gross Profit | $140.78M | $131.83M | $133.19M | $117.57M | $90.77M |
| Gross Margin | 45.9% | 44.5% | 48.2% | 48.6% | 48.1% |
| Operating Income | $-69,806,000 | $-126,897,000 | $-140,005,000 | $-143,650,000 | $-96,125,000 |
| Net Income | $-69,502,000 | $-118,147,000 | $-137,403,000 | $-153,210,000 | $-115,017,000 |
| Net Margin | -22.7% | -39.9% | -49.7% | -63.3% | -60.9% |
| EPS | $-1.15 | $-2.09 | $-2.56 | $-3.23 | $-2.91 |
Company Overview
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
17%
Hold / Neutral
10
83%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
2 Bullish10 Neutral/Bearish
Price Targets
$13
Average Target
↑ 448.6% Upside
Now
$4
Low
$13
Average
$39
High
Based on 18 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 27th 2025 | Piper Sandler | Downgrade | Neutral | $4 |
| August 11th 2025 | Citigroup | Downgrade | Neutral | - |
| August 8th 2025 | Cantor Fitzgerald | Downgrade | Neutral | $4 |
| June 17th 2025 | BTIG Research | Downgrade | Neutral | - |
| April 9th 2025 | Evercore ISI | Downgrade | In-line | - |
| January 8th 2025 | KeyBanc Capital Markets | Upgrade | Overweight | $9 |
| April 10th 2024 | KeyBanc Capital Markets | Downgrade | Sector Weight | - |
| January 3rd 2024 | Barclays | Initiation | Overweight | $14 |
| January 3rd 2024 | Evercore ISI | Upgrade | Outperform | $11 |
| December 13th 2023 | JP Morgan | Upgrade | Overweight | $11← $14 |
| November 13th 2023 | Piper Sandler | Upgrade | Overweight | $11← $12 |
| August 1st 2023 | Cantor Fitzgerald | Initiation | Overweight | $16 |
| May 10th 2023 | Raymond James | Downgrade | Market Perform | - |
| May 10th 2023 | Guggenheim | Downgrade | Neutral | - |
| April 20th 2023 | KeyBanc Capital Markets | Upgrade | Overweight | $16 |
Earnings History & Surprises
HCATBeat Rate
78%
Last 18 quarters
Avg Surprise
+248.6%
EPS vs Estimate
Beats / Misses
14/3
1 met exactly
Latest EPS
$0.06
Q4 2025
EPS Surprise History
Q1 24
+2716.9%
$0.02vs$0.00
Q2 24
+79.0%
$0.05vs$0.03
Q3 24
+33.3%
$0.12vs$0.09
Q4 24
-30.0%
$0.07vs$0.10
Q1 25
-63.6%
$0.04vs$0.11
Q2 25
0.0%
$0.01vs$0.01
Q3 25
+33.3%
$0.04vs$0.03
Q4 25
+20.0%
$0.06vs$0.05
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $0.09 | — | — | — |
Q4 2025 | Nov 10, 2025 | $0.05 | $0.06 | +20.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $0.03 | $0.04 | +33.3% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.01 | $0.01 | 0.0% | = MET |
Q1 2025 | Feb 26, 2025 | $0.11 | $0.04 | -63.6% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $0.10 | $0.07 | -30.0% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $0.09 | $0.12 | +33.3% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $0.03 | $0.05 | +79.0% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $0.00 | $0.02 | +2716.9% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $0.01 | $0.03 | +275.5% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $0.00 | $0.05 | +1448.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $0.02 | $0.05 | +222.8% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.10 | $-0.05 | +50.0% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.20 | $-0.13 | +35.0% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.11 | $-0.03 | +72.7% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.08 | $-0.06 | +25.0% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-0.21 | $-0.19 | +9.5% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.22 | $-0.18 | +18.2% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.14 | $-0.80 | -470.2% | ✗ MISS |
Latest News
Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2.75
➖ NeutralBenzinga•Jan 9, 2026, 04:01 PM•Also:
Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $3.25
➖ NeutralBenzinga•Nov 11, 2025, 08:22 PM•Also:
Stifel Maintains Hold on Health Catalyst, Lowers Price Target to $3.75
📉 NegativeBenzinga•Nov 11, 2025, 03:55 PM•Also:
Wells Fargo Maintains Overweight on Health Catalyst, Lowers Price Target to $5
➖ NeutralBenzinga•Nov 11, 2025, 02:30 PM
Health Catalyst's Twistle By Health Catalyst, Lumeon By Health Catalyst, And Upfront By Health Catalyst Achieve HITRUST r2 Certification
📈 PositiveBenzinga•Nov 10, 2025, 09:16 PM
Health Catalyst Sees Q4 Sales $73.500M vs $76.016M Est
📉 NegativeBenzinga•Nov 10, 2025, 09:04 PM
Health Catalyst Affirms FY2025 Sales Guidance of $310.000M vs $312.152M Est
📉 NegativeBenzinga•Nov 10, 2025, 09:04 PM
Health Catalyst Q3 Adj. EPS $0.06, Inline, Sales $76.323M Beat $75.900M Estimate
📈 PositiveBenzinga•Nov 10, 2025, 09:04 PM
Evercore ISI Group Maintains In-Line on Health Catalyst, Lowers Price Target to $3
➖ NeutralBenzinga•Oct 8, 2025, 01:18 PM
Keybanc Maintains Overweight on Health Catalyst, Lowers Price Target to $4
➖ NeutralBenzinga•Oct 8, 2025, 01:12 PM
Cantor Fitzgerald Reiterates Neutral on Health Catalyst, Maintains $4 Price Target
➖ NeutralBenzinga•Oct 7, 2025, 01:14 PM
Healthmine Appoints Dwight Erskine As CEO
➖ NeutralBenzinga•Sep 24, 2025, 12:33 PM
Health Catalyst Appoints Ben Albert As President And COO
➖ NeutralBenzinga•Sep 10, 2025, 08:05 PM
BTIG Reiterates Neutral on Health Catalystto Neutral
➖ NeutralBenzinga•Sep 5, 2025, 10:46 AM
Canaccord Genuity Maintains Buy on Health Catalyst, Lowers Price Target to $5
➖ NeutralBenzinga•Aug 29, 2025, 06:01 PM•Also:
Evercore ISI Group Maintains In-Line on Health Catalyst, Raises Price Target to $4
📈 PositiveBenzinga•Aug 28, 2025, 12:42 PM
Piper Sandler Downgrades Health Catalyst to Neutral, Lowers Price Target to $4
📉 NegativeBenzinga•Aug 27, 2025, 01:19 PM
Health Catalyst tanks after FY revenue outlook cut, Cantor downgrade
📉 NegativeSeeking Alpha•Aug 8, 2025, 02:42 PM
Frequently Asked Questions about HCAT
What is HCAT's current stock price?
Health Catalyst, Inc. (HCAT) is currently trading at $2.40 per share. The stock has moved -2.44% today.
What is the analyst price target for HCAT?
The average analyst price target for HCAT is $4.86, based on 1 analyst.
What sector is Health Catalyst, Inc. in?
Health Catalyst, Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NASDAQ exchange.
What is HCAT's market cap?
Health Catalyst, Inc. has a market capitalization of $0.17 billion, making it a small-cap company.
Does HCAT pay dividends?
No, Health Catalyst, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCRBU
Caribou Biosciences, Inc.
$1.59
Mkt Cap: $0.1B
ENTA
Enanta Pharmaceuticals, Inc.
$13.13
Mkt Cap: $0.3B
HSDT
Solana Company
$3.45
Mkt Cap: $0.1B
NNOX
Nano-X Imaging Ltd.
$3.04
Mkt Cap: $0.2B
OBIO
Orchestra BioMed Holdings, Inc.
$4.28
Mkt Cap: $0.2B
OM
Outset Medical, Inc.
$5.12
Mkt Cap: $0.1B
PRLD
Prelude Therapeutics Incorporated
$2.24
Mkt Cap: $0.2B
PYXS
Pyxis Oncology, Inc.
$1.88
Mkt Cap: $0.1B
SNWV
SANUWAVE Health, Inc.
$28.57
Mkt Cap: $0.2B
TNYA
Tenaya Therapeutics, Inc.
$0.76
Mkt Cap: $0.1B
Explore stocks similar to HCAT for comparison